Gara Jalqabaatti › Kansaarii Pirostaatikii Itti Falmu › California
Qorannoo klinikaalii Kansaarii Pirostaatikii Itti Falmu California keessatti
Qorannoo 11 Kansaarii Pirostaatikii Itti Falmu f California keessatti hirmaatuu jiru.
Magaalota California keessatti
Takkalaa qorannoo (Ingiliffa)
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- University of California at San Diego, La Jolla
- Cedars Sinai Medical Center, Los Angeles
- Ronald Reagan UCLA Medical Center, Los Angeles
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dhiroota · Haaromfame 25-Ful-2026 · NCT07164443A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- MemorialCare Orange Coast Medical Center, Fountain Valley
- University Of California San Diego, La Jolla
- Cancer and Blood Specialty Clinic, Los Alamitos
- fi 6 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07225946A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- START Los Angeles, Los Angeles
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Dhiroota · Haaromfame 24-Ful-2026 · NCT07719361Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- UCSD Moores Cancer Center ( Site 0039), La Jolla
- UCLA Hematology/Oncology - Santa Monica ( Site 0044), Los Angeles
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT06353386A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- UCLA Hematology & Oncology ( Site 0003), Los Angeles
- University of California-Irvine Medical Center ( Site 0016), Orange
- UCSF Medical Center at Mission Bay ( Site 0034), San Francisco
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT06863272Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- UCI Health Chao Family Comprehensive Cancer Center, Orange
- Investigational Site Number: 403, Palo Alto
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Dhiroota · Haaromfame 10-Ful-2026 · NCT05997615Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- USC Norris Comprehensive Cancer Center, Los Angeles
- UCLA Department of Medicine, Los Angeles
- Hoag Memorial Hospital Presbyterian, Newport Beach
- fi 2 dabalataa
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 100 · Dhiroota · Haaromfame 13-Hag-2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
- The Angeles Clinic and Research Institute, Los Angeles
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Stanford Cancer Center, Palo Alto
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Dhiroota · Haaromfame 10-Hag-2026 · NCT0606784164Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
- Stanford Cancer Institute, Stanford
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Dhiroota · Haaromfame 06-Cam-2026 · NCT0486860418F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- VA Greater Los Angeles Healthcare System, Los Angeles
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 fi ol · Dhiroota · Haaromfame 27-Sad-2024 · NCT06706921Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.